- Anixa Biosciences received a Notice of Allowance from the Canadian Intellectual Property Office for a patent covering key aspects of its AMHR2-targeted ovarian cancer vaccine technology, exclusively licensed from Cleveland Clinic.
- The patent covers methods of administering a nucleic acid-based immunogenic composition that stimulates an AMHR2-specific immune response, with potential applications in preventing and treating ovarian cancer.
- The Canadian allowance expands Anixa’s international intellectual property portfolio and complements its US patent issued in 2025, strengthening protection around its ovarian cancer vaccine platform.
- The ovarian cancer vaccine is being developed with Cleveland Clinic and the National Cancer Institute, while Anixa continues advancing its broader cancer vaccine portfolio, including a breast cancer vaccine that recently completed a Phase 1 trial and met all primary endpoints.
Takeaways:
This notice of allowance shores up Anixa’s IP moat around its AMHR2‑targeted ovarian cancer vaccine and aligns Canada with its existing US patent protection.
For the market, stronger international patent coverage de‑risks partnering and long-term value capture around a preventive/therapeutic ovarian cancer vaccine, while also supporting Anixa’s broader “retired‑protein” cancer vaccine platform, which already includes a breast cancer vaccine that met safety and immune‑response endpoints in Phase 1.
Source: Anixa
